Mycophenolate mofetil for the treatment of takayasu arteritis: Report of three cases

Erica Daina, Arrigo Schieppati, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


Background: Takayasu arteritis is a rare form of chronic inflammatory disease of the large arterial vessels. Some patients do not respond to steroids or immunosuppressant drugs. Objective: To evaluate the effect of mycophenolate mofetil in patients with severe Takayasu arteritis, Design: Case series. Setting: Clinical Research Center for Rare Diseases in Bergamo, Italy. Patients: Three patients with Takayasu arteritis. Intervention: Mycophenolate mofetil (2 g/d) given orally in two divided doses. Measurements: Clinical evaluation and assessment of leukocyte counts were done weekly. Vascular lesions were assessed by using Doppler ultrasonography. Results: All patients showed clinical benefit, and two resumed work after months of inactivity. Patients were also able to taper and discontinue steroid use. Mycophenolate mofetil was well tolerated, and no signs of toxicity were observed. Conclusions: Mycophenolate mofetil may be an alternative to steroids and cytotoxic agents in patients with Takayasu arteritis. Before results of controlled trials become available, mycophenolate mofetil should be considered only for patients who do not improve or stabilize with conventional therapy.

Original languageEnglish
Pages (from-to)422-426
Number of pages5
JournalAnnals of Internal Medicine
Issue number5
Publication statusPublished - Mar 2 1999

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Mycophenolate mofetil for the treatment of takayasu arteritis: Report of three cases'. Together they form a unique fingerprint.

Cite this